As of December 31, 2022, cash, cash equivalents and marketable securities were $283.1M as compared with $166M as of December 31, 2021. Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2026. "As announced in our release earlier this month, 2023 promises to be another transformative year for Terns as we make meaningful strides to advance our pipeline of medicines to address serious unmet needs. In addition to data from our Phase 2a DUET trial in NASH, expected in the third quarter of 2023, we also anticipate key clinical readouts in 2024 from our clinical trials in chronic myeloid leukemia and obesity. We are fortunate to have a strong balance sheet to support development activities and the growth of our company into 2026," said Mark Vignola, chief financial officer of Terns.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TERN:
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
- Terns Pharmaceuticals appoints Kuriakose as CMO of Terns oncology
- Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology
- TipRanks ‘Perfect 10’ List: 3 Top-Rated Stocks That Tick All the Right Boxes
- Terns Pharmaceuticals management to meet virtually with Piper Sandler
